GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their
efficacy is documented. However, safety aspects are also important to evaluate with respect
to micro and macrovascular complications associated with T2D. Few studies have properly
addressed the role of GLP-1-based therapies in regulating vascular integrity and
angiogenesis. The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2
and ANGLPT4 levels and endothelial circulating progenitor cells, angiogenesis biomarkers in
type 2 diabetic patients.